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Is serology predictive of persisting villous atrophy in patients with 
established Coeliac Disease (CD)? 
 
Introduction: 
 
Recent work has suggested that an IgA-tissue transglutaminase (IgA tTG) <1.2 
U/mL may predict mucosal healing in those with established CD. This study 
examines whether the combination of serological markers may be used as a 
surrogate marker for the detection of villous atrophy (VA) in known CD patients. 
 
Methods: 
We undertook a prospective analysis of known Coeliac disease (CD) patients 
diagnosed in a University hospital. All patients underwent a gastroscopy, with 
four biopsies taken from the second part of the duodenum, and one from the 
duodenal bulb. Serological markers were assessed at the time of endoscopy (IgA 
tTG, IgA-endomysial antibodies (IgA-EMA), IgA-antigliadin antibody (IgA AGA) 
and IgG-anti-gliadin antibody (IgG AGA), and their performances in isolation and 
in combination compared to histological outcomes.  
 
Results: 
107 patients (67.3% female,  median age 53 years (20-81 years)) that were on a 
gluten-free diet for a median duration of 6 years were included. The 
performance of the different serological markers to detect VA, both in isolation 
and in combination are shown in Table 1. The performance of TTG using the 
previously used cutoff of <1.2u/ml produced a sensitivity of 38.5%, a specificity 
of 73.8%, a positive predictive value of 64.9% and a negative predictive value of 
43.7% to detect VA. 
 
Table 1 - Ability of serological markers to detect VA 
 Sensitivity Specificity Positive 
Predictive 
value 
Negative 
Predictive 
Value 
tTG 39.0% 97.1% 88.9% 70.8% 
EMA 40.5% 78.8% 89.5% 71.6% 
IgA AGA 47.5% 95.5% 86.3% 75.3% 
IgG AGA 37.5% 90.0% 68.2% 71.6% 
EMA + tTG 33.3% 1.54% 93.3% 30.4% 
IgA AGA + 
IgG AGA 
28.6% 100% 100% 68.4% 
IgA or IgG + 
EMA 
28.6% 100% 100% 68.4% 
IgA or IgG + 
tTG 
31.0% 100% 100% 69.1% 
 
Conclusions: 
This study is the first study to evaluate the combination of serological markers to 
detect VA in patients with established CD. Our findings oppose recent work that 
serology may be used as a surrogate marker of mucosal healing in known CD.   
